pyruvate family amino acid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	pyruvate family amino acid	go back to main search page
Accession:	CHEBI:26463	browse the term
Definition:	An L-alpha-amino acid which is biosynthesised from pyruvate (i.e. alanine, valine, and leucine). A closed class.
Synonyms:	related_synonym:	pyruvate family amino acids

show annotations for term's descendants Sort by:
Rat (323) Mouse (324) Human (327) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (323)

3-(5-fluorouracil-1-yl)-L-alanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamate ionotropic receptor AMPA type subunit 3

affects response to substance

GRIA3 protein affects the susceptibility to 5-fluorowillardiine

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096

alliin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cathepsin D

multiple interactions

alliin affects the reaction [Isoproterenol affects the activity of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

fatty acid synthase

multiple interactions

alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of FASN mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of FASN protein]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 2

decreases secretion
multiple interactions

alliin results in decreased secretion of FGF2 protein
alliin promotes the reaction [FGF2 protein results in increased expression of TP53 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

alliin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein]
alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR protein]

PMID:16640830 PMID:29305303

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

lecithin cholesterol acyltransferase

multiple interactions

alliin inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein]

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

sterol regulatory element binding transcription factor 1

multiple interactions

alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

multiple interactions

alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 protein]

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

tumor protein p53

multiple interactions

alliin promotes the reaction [FGF2 protein results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

decreases secretion

alliin results in decreased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

aloxistatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calpain 1

multiple interactions

aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

calpain 7

multiple interactions

aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]

NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905

G

caspase 3

multiple interactions

[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]
[Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein

PMID:26853465 PMID:33186601

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cathepsin B

multiple interactions

[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]

PMID:30910806 PMID:32186374

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

multiple interactions

aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

DEAD-box helicase 3, X-linked

multiple interactions

aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]

NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168

G

eukaryotic translation initiation factor 4A1

multiple interactions

aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]

NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858

G

eukaryotic translation initiation factor 4H

multiple interactions

aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]

NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

lysosomal-associated membrane protein 2

multiple interactions

[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases lipidation

[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein]
aloxistatin results in increased lipidation of MAP1LC3B protein
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein

PMID:26483381 PMID:27635674 PMID:32397857 PMID:33124469

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

sequestosome 1

multiple interactions
increases expression

[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein]
aloxistatin results in increased expression of SQSTM1 protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein

PMID:26483381 PMID:32186374 PMID:32773031 PMID:33124469

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

L-alanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

DEK proto-oncogene

multiple interactions

DEK protein results in increased chemical synthesis of and results in increased secretion of Alanine

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

isocitrate dehydrogenase (NADP(+)) 2

decreases abundance
multiple interactions

IDH2 protein mutant form results in decreased abundance of Alanine
Triazines inhibits the reaction [IDH2 protein mutant form results in decreased abundance of Alanine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

L-leucine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

autophagy related 5

multiple interactions

Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions

Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

beclin 1

multiple interactions

Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

multiple interactions

Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

epidermal growth factor

multiple interactions

[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

myeloperoxidase

multiple interactions

Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

solute carrier family 3 member 2

affects import

SLC3A2 protein affects the import of Leucine

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 7 member 8

affects import

SLC7A8 protein affects the import of Leucine

NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717

G

sequestosome 1

multiple interactions

Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

L-selenocysteine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminolevulinate dehydratase

decreases activity

Selenocysteine analog results in decreased activity of ALAD protein

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Selenocysteine inhibits the reaction [Lipopolysaccharides affects the localization of and affects the activity of FOS protein]; Selenocysteine inhibits the reaction [Peroxynitrous Acid affects the localization of and affects the activity of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutathione S-transferase alpha 2

increases expression

Selenocysteine results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 3

increases expression

Selenocysteine results in increased expression of GSTA3 mRNA

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 5

increases expression

Selenocysteine results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase pi 1

increases expression

Selenocysteine results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Selenocysteine inhibits the reaction [Lipopolysaccharides affects the localization of and affects the activity of RELA protein]; Selenocysteine inhibits the reaction [Peroxynitrous Acid affects the localization of and affects the activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

LCL161

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

LCL161 binds to and affects the activity of ABCB1 protein; LCL161 inhibits the reaction [ABCB1 protein results in increased export of Fluorescent Dyes]; LCL161 inhibits the reaction [ABCB1 protein results in increased export of mitotracker green FM]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

baculoviral IAP repeat-containing 2

decreases expression
decreases expression

LCL161 results in decreased expression of BIRC2 protein
LCL161 decreases expression of BIRC2 protein in hepatocellular carcinoma cells

CTD
RGD

PMID:32497533 PMID:24976294

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

decreases expression

LCL161 decreases expression of BIRC3 protein in hepatocellular carcinoma cells

RGD

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression

LCL161 results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

X-linked inhibitor of apoptosis

decreases expression

LCL161 decreases expression of XIAP protein in hepatocellular carcinoma cells

RGD

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

ledipasvir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

affects binding

ledipasvir binds to ABCG2 protein

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

killer cell lectin like receptor C1

decreases expression

ledipasvir co-treated with sofosbuvir decreases expression of NCR1 protein in natural killer cells

RGD

NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425

G

natural cytotoxicity triggering receptor 1

affects expression

ledipasvir co-treated sofosbuvir with affects expression of NCR1 protein in natural killer cells

RGD

NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558

Leu-enkephalin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dipeptidylpeptidase 3

increases cleavage
multiple interactions

DPP3 protein results in increased cleavage of Enkephalin, Leucine
spinorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]; tynorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]

NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541

G

opioid receptor, delta 1

increases activity

Enkephalin, Leucine results in increased activity of OPRD1 protein

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, mu 1

increases activity

Enkephalin, Leucine results in increased activity of OPRM1 protein

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

metalaxyl

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

metalaxyl results in decreased expression of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

metalaxyl results in decreased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

methyl L-leucinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

multiple interactions

leucine methyl ester inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

N-benzoyl-L-alanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor coactivator 2

multiple interactions

N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

thyroid hormone receptor alpha

multiple interactions

N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions
affects binding

N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]
N-benzoylalanine binds to THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

N-formyl-L-methionyl-L-leucyl-L-phenylalanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosine deaminase

multiple interactions

ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]

PMID:15925284 PMID:16621998 PMID:34144024

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 5-lipoxygenase

multiple interactions

[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein; SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein]

PMID:9495842 PMID:10779545 PMID:11116075

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

ADP-ribosylation factor 1

affects localization

N-Formylmethionine Leucyl-Phenylalanine affects the localization of ARF1 protein

NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434

G

ADP-ribosylation factor 6

multiple interactions
affects localization

1-Butanol inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 1-Butanol inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]; ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]
N-Formylmethionine Leucyl-Phenylalanine affects the localization of ARF6 protein

NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114

G

BCL2 associated X, apoptosis regulator

increases activity

N-Formylmethionine Leucyl-Phenylalanine results in increased activity of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions
increases activity

Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions
increases activity

Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

CD38 molecule

increases cleavage
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein
SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein]

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

Cd63 molecule

multiple interactions
increases expression

Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; Quercetin affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; SB 203580 inhibits the reaction [Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]]

PMID:19887118 PMID:22036725

NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178

G

cathepsin G

multiple interactions
increases secretion

cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]

PMID:25980585 PMID:34144024

NCBI chr15:29,930,988...29,937,353
Ensembl chr15:29,931,003...29,937,353

G

cytochrome b-245 beta chain

increases activity
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein
diphenyleneiodonium inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein]; Genistein inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

elastase, neutrophil expressed

multiple interactions
increases secretion

2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of ELANE protein]; [Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein; pirinixic acid analog inhibits the reaction [[Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein]

PMID:19686721 PMID:21457779

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

multiple interactions
increases expression

Quercetin affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ENPP3 protein]

NCBI chr 1:20,563,700...20,635,044
Ensembl chr 1:20,563,697...20,635,041

G

FGR proto-oncogene, Src family tyrosine kinase

multiple interactions
increases phosphorylation

1-Butanol inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with dihydrocytochalasin B] results in increased activity of FGR protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of FGR protein

PMID:11078731 PMID:25980585

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

formyl peptide receptor 1

multiple interactions

N-Formylmethionine Leucyl-Phenylalanine binds to and results in increased activity of FPR1 protein

NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559

G

glucuronidase, beta

increases secretion
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein
epigallocatechin gallate inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein]

PMID:9545557 PMID:11944907

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

HCK proto-oncogene, Src family tyrosine kinase

increases phosphorylation

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of HCK protein

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

interleukin 1 beta

multiple interactions
increases expression

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 3

increases response to substance

IL3 protein results in increased susceptibility to N-Formylmethionine Leucyl-Phenylalanine

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

multiple interactions
increases expression

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha 2b

multiple interactions

ITGA2B protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]

NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168

G

integrin subunit alpha M

multiple interactions
increases expression

2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; dimemorfan inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; KT 5720 inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Staurosporine inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]
fMLP increases expression of ITGAM protein on neutrophils and monocytes
[N-formyl-methionyl-leucyl-phenylalanine cotreated with midazolam] decreases expression of ITGAM protein on neutrophils

CTD
RGD

PMID:10215738 PMID:11116075 PMID:15774851 PMID:18500357 PMID:21457779 More...

RGD:329901666, RGD:329853762

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

increases expression
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; crenatoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]

PMID:10215738 PMID:16393473 PMID:21664406

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

integrin subunit beta 3

increases expression

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB3 protein

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

LYN proto-oncogene, Src family tyrosine kinase

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein]

NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868

G

lysozyme 2

increases secretion

N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of LYZ protein

NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]
RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]

PMID:11145705 PMID:11427526 PMID:15494208 PMID:16212921 PMID:16621998 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions
increases phosphorylation

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK14 protein; Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]

PMID:16621998 PMID:17406807

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]
RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]

PMID:11145705 PMID:11427526 PMID:15494208 PMID:16212921 PMID:16621998 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein]
MAPK8 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein

PMID:17377739 PMID:17560994

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

matrix metallopeptidase 8

increases expression

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MMP8 protein

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

myeloperoxidase

multiple interactions
increases activity
increases secretion
increases expression

carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MPO protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein
N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein
carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]; diphenyleneiodonium inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]; Sodium Azide inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]

PMID:16601795 PMID:17159805 PMID:18987595 PMID:22906169

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

neutrophil cytosolic factor 1

multiple interactions
affects localization

AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; bisindolylmaleimide I inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

platelet and endothelial cell adhesion molecule 1

increases expression

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PECAM1 protein

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

phospholipase A2 group 4A

multiple interactions

PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase A2, group V

increases activity
multiple interactions
increases secretion

N-Formylmethionine Leucyl-Phenylalanine results in increased activity of PLA2G5 protein
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid]; PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]
N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of PLA2G5 protein

PMID:9495842 PMID:11741884

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

phospholipase C, gamma 2

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]

NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930

G

phospholipase D1

multiple interactions

PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species]

PMID:11427526 PMID:17560994

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

platelet-activating factor receptor

multiple interactions

PTAFR protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 2

increases expression

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Rac family small GTPase 1

increases activity
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein
6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]

PMID:16621998 PMID:28779020

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

Rac family small GTPase 2

increases activity
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein
6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]

PMID:11145705 PMID:16621998 PMID:28779020

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

ras homolog family member G

multiple interactions
affects response to substance

RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]
RHOG protein affects the susceptibility to N-Formylmethionine Leucyl-Phenylalanine

NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257

G

selectin L

increases expression

N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELL protein

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

selectin P

multiple interactions
increases expression

ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; ITGA2B protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; MK-886 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; PTAFR protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; SR 121566 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; zileuton inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

SRC proto-oncogene, non-receptor tyrosine kinase

increases phosphorylation
multiple interactions

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]

PMID:25980585 PMID:34144024

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

tec protein tyrosine kinase

multiple interactions
affects localization

AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein]

NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557

G

tumor necrosis factor

multiple interactions
increases expression

[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides; Cyclosporine inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of TNF protein

PMID:11121130 PMID:12946449

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

decreases response to substance

TNFAIP6 protein modified form results in decreased susceptibility to N-Formylmethionine Leucyl-Phenylalanine

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

vav guanine nucleotide exchange factor 1

increases phosphorylation

N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of VAV1 protein

NCBI chr 9:2,161,985...2,209,951
Ensembl chr 9:2,157,900...2,208,937

G

vascular endothelial growth factor A

multiple interactions
increases expression
increases secretion

Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA protein

PMID:17377739 PMID:17459229 PMID:17520823

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

orlistat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

abhydrolase domain containing 12, lysophospholipase

decreases activity

orlistat results in decreased activity of ABHD12 protein

NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564

G

abhydrolase domain containing 16A, phospholipase

decreases activity

orlistat results in decreased activity of ABHD16A protein

NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927

G

acetyl-CoA carboxylase alpha

multiple interactions
decreases expression

Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
Orlistat results in decreased expression of ACACA mRNA

PMID:32347045 PMID:33476690

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetylcholinesterase

decreases activity

Orlistat results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA thioesterase 8

decreases expression

Orlistat results in decreased expression of ACOT8 protein

NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851

G

adiponectin, C1Q and collagen domain containing

multiple interactions

orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]

PMID:25087745 PMID:33476690

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activating transcription factor 4

increases expression

orlistat results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

BCL2 associated X, apoptosis regulator

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases activity
increases cleavage
multiple interactions

orlistat results in increased activity of CASP3 protein
orlistat results in increased cleavage of CASP3 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]

PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]

PMID:18796435 PMID:20577697 PMID:32450208

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions

orlistat results in increased activity of CASP9 protein
Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA]

PMID:20805790 PMID:32450208

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
decreases expression

Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein]
Orlistat results in decreased expression of CAT protein

PMID:25087745 PMID:30667213 PMID:32450208

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

multiple interactions
decreases secretion

[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein]
orlistat results in decreased secretion of CCK protein

PMID:11408251 PMID:18303078 PMID:18647814

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

cyclin A2

decreases expression

Orlistat results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

increases expression
multiple interactions

Orlistat results in increased expression of CCND1 protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]

PMID:30667213 PMID:32045588

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

increases expression

Orlistat results in increased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

CD34 molecule

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

cyclin-dependent kinase 1

decreases expression

Orlistat results in decreased expression of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases expression

Orlistat results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Orlistat results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1A

increases expression

Orlistat results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

orlistat results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

multiple interactions

Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

carboxyl ester lipase

decreases activity

orlistat results in decreased activity of CEL protein

PMID:11592731 PMID:12381337

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

colipase

multiple interactions

orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]

NCBI chr20:6,620,529...6,622,709
Ensembl chr20:6,620,529...6,622,689

G

carboxypeptidase B2

decreases expression

orlistat results in decreased expression of CPB2 protein

NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556

G

carnitine palmitoyltransferase 1A

decreases expression

Orlistat results in decreased expression of CPT1A protein

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

decreases expression

Orlistat results in decreased expression of CPT2 protein

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

diacylglycerol lipase, alpha

decreases activity

orlistat results in decreased activity of DAGLA protein

NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232

G

DNA-damage inducible transcript 3

increases expression

orlistat results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

increases expression

orlistat results in increased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

eukaryotic translation initiation factor 2A

increases phosphorylation
multiple interactions

orlistat results in increased phosphorylation of EIF2A protein
orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein
Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein]
orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]

PMID:17283163 PMID:20577697

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases response to substance
multiple interactions

EIF2AK3 gene mutant form results in increased susceptibility to orlistat
orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 4E

increases phosphorylation

orlistat results in increased phosphorylation of EIF4E protein

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

erb-b2 receptor tyrosine kinase 2

affects response to substance
decreases expression
affects localization

ERBB2 protein affects the susceptibility to orlistat
orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein
orlistat affects the localization of ERBB2 protein

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ETS variant transcription factor 4

increases expression

orlistat results in increased expression of ETV4 protein

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

fatty acid binding protein 1

decreases expression

Orlistat results in decreased expression of FABP1 protein

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fas cell surface death receptor

decreases expression

Orlistat results in decreased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

affects binding
affects response to substance
multiple interactions
decreases activity
decreases expression

orlistat analog binds to FASN protein
FASN protein affects the susceptibility to orlistat
[Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone]
orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein
[orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid]
Orlistat results in decreased expression of FASN protein

PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 More...

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glucagon

multiple interactions
decreases expression
decreases secretion

orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein]
orlistat results in decreased expression of GCG protein
orlistat results in decreased secretion of GCG protein

PMID:12915676 PMID:18647814 PMID:19837920

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

ghrelin and obestatin prepropeptide

multiple interactions

orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein]

PMID:15998659 PMID:17138722

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

gastric inhibitory polypeptide

decreases expression

orlistat results in decreased expression of GIP protein

NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503

G

glutamic--pyruvic transaminase

multiple interactions

orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 8

increases expression

orlistat results in increased expression of GPX8 mRNA

NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195

G

glutathione-disulfide reductase

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hemoglobin alpha, adult chain 2

decreases expression

orlistat results in decreased expression of HBA1 protein modified form

PMID:19207292 PMID:19461584

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein]

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heat shock protein family A (Hsp70) member 5

increases expression

orlistat results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 10

increases expression

Orlistat results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

PMID:21088047 PMID:32045588

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

decreases expression
increases expression
affects expression
multiple interactions

orlistat results in decreased expression of INS protein
orlistat results in increased expression of INS protein
orlistat affects the expression of INS protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]

PMID:10095983 PMID:11274935 PMID:12915676 PMID:33476690

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

KDEL endoplasmic reticulum protein retention receptor 3

increases expression

orlistat results in increased expression of KDELR3 mRNA

NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600

G

kinase insert domain receptor

decreases expression

orlistat results in decreased expression of KDR protein

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

keratin 81

increases expression

orlistat results in increased expression of KRT81 mRNA

NCBI chr 7:132,577,112...132,582,238
Ensembl chr 7:132,576,492...132,582,170

G

lecithin cholesterol acyltransferase

multiple interactions

orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein]

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

leptin

multiple interactions

orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein]

PMID:21332399 PMID:25087745

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase F, gastric type

decreases activity

orlistat results in decreased activity of LIPF protein

PMID:11408251 PMID:12381337

NCBI chr 1:231,493,498...231,511,845
Ensembl chr 1:231,493,498...231,511,845

G

lipoprotein lipase

decreases activity
multiple interactions

orlistat results in decreased activity of LPL protein
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein]
orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein]
[orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides

PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 More...

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

mitogen activated protein kinase 1

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

N-acyl phosphatidylethanolamine phospholipase D

decreases activity

orlistat results in decreased activity of NAPEPLD protein

NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748

G

NFE2 like bZIP transcription factor 2

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA

PMID:32450208 PMID:33476690

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 2

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuropeptide Y

increases expression

orlistat results in increased expression of NPY protein

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 1, group I, member 2

increases activity

orlistat results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

Orlistat binds to and results in increased activity of NR1I3 protein alternative form

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

neurotensin

multiple interactions

Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein]

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

[orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein
orlistat results in increased cleavage of PARP1 protein

PMID:15870086 PMID:17283163

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phospholipase A2 group VII

decreases activity
multiple interactions

orlistat results in decreased activity of PLA2G7 protein
[orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein

PMID:16911813 PMID:18513463 PMID:18657971

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

pancreatic lipase

decreases secretion
decreases activity
multiple interactions
affects folding

orlistat results in decreased secretion of PNLIP protein
orlistat results in decreased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
orlistat affects the folding of PNLIP protein
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]

PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257

NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654

G

pancreatic lipase related protein 2

decreases activity

orlistat results in decreased activity of PNLIPRP2 protein
Orlistat results in decreased activity of PNLIPRP2 protein

PMID:9822688 PMID:17401110

NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434

G

paraoxonase 1

increases activity

orlistat results in increased activity of PON1 protein

PMID:11820148 PMID:17134960

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator-activated receptor delta

multiple interactions

Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

increases expression

Orlistat results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

palmitoyl-protein thioesterase 1

decreases expression

Orlistat results in decreased expression of PPT1 protein

NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048

G

pancreatic polypeptide

multiple interactions

orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein]

NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,054,756...87,055,455

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein]
orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]

PMID:18390901 PMID:19167487

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

phosphatase and tensin homolog

increases expression
multiple interactions

Orlistat results in increased expression of PTEN protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

peptide YY

decreases secretion
multiple interactions

orlistat results in decreased secretion of PYY protein
orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]

PMID:15998659 PMID:17138722 PMID:18647814

NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,061,161...87,061,815

G

RB transcriptional corepressor 1

decreases phosphorylation

orlistat results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

SEC24 homolog D, COPII coat complex component

increases expression

orlistat results in increased expression of SEC24D mRNA

NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587

G

S-phase kinase associated protein 2

multiple interactions
decreases expression

[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein
orlistat results in decreased expression of SKP2 protein

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 22 member 2

multiple interactions

orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]
Orlistat results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transferrin

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transforming growth factor, beta 1

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]

PMID:15994321 PMID:32045588 PMID:32450208

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

increases response to substance

orlistat results in increased susceptibility to TNFSF10 protein

PMID:18796435 PMID:21406729

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tumor protein p53

multiple interactions

Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

uncoupling protein 1

multiple interactions

Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

X-box binding protein 1

multiple interactions

orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

ritonavir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

Ritonavir results in decreased activity of ABCB11 protein
Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

PMID:20829430 PMID:22646477 PMID:23956101 PMID:24014644 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions

hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

decreases expression
decreases activity

Ritonavir results in decreased expression of ABCB4
Ritonavir results in decreased activity of ABCB4 protein

PMID:26626330 PMID:28437613

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

acyl-CoA synthetase short-chain family member 2

affects expression

Ritonavir affects the expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

adiponectin, C1Q and collagen domain containing

decreases expression
multiple interactions

Ritonavir results in decreased expression of ADIPOQ mRNA; Ritonavir results in decreased expression of ADIPOQ protein
rosiglitazone inhibits the reaction [Ritonavir results in decreased secretion of ADIPOQ protein]
diphenyleneiodonium inhibits the reaction [Ritonavir results in decreased expression of ADIPOQ protein]

PMID:15865214 PMID:17668557

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

increases phosphorylation

Ritonavir results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

affects binding

Ritonavir binds to ALB protein

PMID:15814459 PMID:16336266

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

BCL2-antagonist/killer 1

increases expression

Ritonavir results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2, apoptosis regulator

decreases expression

Ritonavir results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

Ritonavir results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

baculoviral IAP repeat-containing 5

decreases expression

Ritonavir results in decreased expression of BIRC5 mRNA; Ritonavir results in decreased expression of BIRC5 protein

PMID:16174765 PMID:21270666

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 1

decreases expression

Ritonavir results in decreased expression of CASP1 protein

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

decreases activity

Ritonavir results in decreased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions
increases expression
increases secretion
decreases expression

diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein]
Ritonavir results in decreased expression of CCL2

PMID:17668557 PMID:20884875 PMID:26626330

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

decreases expression

Ritonavir results in decreased expression of CCL20

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

decreases expression
increases expression

Ritonavir results in decreased expression of CCL3
Ritonavir results in increased expression of CCL3 protein

PMID:17668557 PMID:26626330

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression

Ritonavir results in decreased expression of CCL4

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

cyclin A2

decreases expression

Ritonavir results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Ritonavir results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

Ritonavir results in decreased expression of CCND1 protein

PMID:16551874 PMID:21270666

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

decreases expression

Ritonavir results in decreased expression of CCND2 mRNA

PMID:16174765 PMID:19386116

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E2

decreases expression

Ritonavir results in decreased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin dependent kinase 2

decreases expression

Ritonavir results in decreased expression of CDK2 mRNA; Ritonavir results in decreased expression of CDK2 protein

PMID:16551874 PMID:19386116

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Ritonavir results in decreased expression of CDK4 mRNA; Ritonavir results in decreased expression of CDK4 protein

PMID:16551874 PMID:19386116

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

decreases expression

Ritonavir results in decreased expression of CDK5 mRNA

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase 6

decreases expression

Ritonavir results in decreased expression of CDK6 mRNA; Ritonavir results in decreased expression of CDK6 protein

PMID:16551874 PMID:19386116

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Ritonavir results in increased expression of CDKN1A mRNA; Ritonavir results in increased expression of CDKN1A protein
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of CDKN1A protein]

PMID:19386116 PMID:20884875

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Ritonavir results in increased expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2B

increases expression

Ritonavir results in increased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

CCAAT/enhancer binding protein alpha

multiple interactions

Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

class II, major histocompatibility complex, transactivator

increases expression

Ritonavir results in increased expression of CIITA

NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440

G

carnitine O-octanoyltransferase

decreases expression

Ritonavir results in decreased expression of CROT mRNA

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

G

C-X-C motif chemokine ligand 1

decreases expression

Ritonavir results in decreased expression of CXCL1

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

decreases expression

Ritonavir results in decreased expression of CXCL10

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

decreases expression

Ritonavir results in decreased expression of CXCL12

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 2

decreases expression

Ritonavir results in decreased expression of CXCL2

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

decreases expression

Ritonavir results in decreased expression of CXCL1

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 6

decreases expression

Ritonavir results in decreased expression of CXCL6

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

cytochrome b5 reductase 3

affects expression

Ritonavir affects the expression of CYB5R3 mRNA

NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
decreases activity

Ritonavir results in increased expression of CYP1A1 mRNA
Ritonavir results in decreased activity of CYP1A1 protein

PMID:11918509 PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
decreases expression

Ritonavir results in increased expression of CYP1A2 mRNA
Ritonavir results in decreased expression of CYP1A2 mRNA

PMID:11918509 PMID:17719200

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Ritonavir results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases activity
increases expression

Ritonavir results in increased activity of CYP2B6 protein
Ritonavir results in increased expression of CYP2B6 protein

PMID:14977870 PMID:26626330

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases expression

Ritonavir results in increased expression of CYP2C19 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Ritonavir results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing

CYP2D6 protein affects the metabolism of Ritonavir

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
decreases activity
affects binding
affects metabolic processing

Ritonavir results in increased expression of CYP3A4 mRNA
Ritonavir results in decreased activity of CYP3A4 protein
CYP3A4 protein binds to Ritonavir analog
CYP3A4 protein affects the metabolism of Ritonavir

PMID:15286053 PMID:15523003 PMID:15860655 PMID:16837568 PMID:26626330 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Ritonavir results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases activity

Ritonavir results in decreased activity of CYP3A5 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 4, subfamily a, polypeptide 3

decreases expression

Ritonavir results in decreased expression of CYP4A3 mRNA

NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463

G

cytochrome P450, family 4, subfamily b, polypeptide 1

affects expression
decreases expression

Ritonavir affects the expression of CYP4B1 mRNA
Ritonavir results in decreased expression of CYP4B1 mRNA

NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348

G

cytochrome P450, family 51

increases expression

Ritonavir results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Ritonavir results in decreased expression of CYP7A1 mRNA

PMID:17719200 PMID:26626330

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Ritonavir results in decreased expression of CYP8B1
Ritonavir results in decreased expression of CYP8B1 mRNA

PMID:17719200 PMID:26626330

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

7-dehydrocholesterol reductase

affects expression

Ritonavir affects the expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

E2F transcription factor 1

decreases expression

Ritonavir results in decreased expression of E2F1 mRNA; Ritonavir results in decreased expression of E2F1 protein

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 2

decreases expression

Ritonavir results in decreased expression of E2F2 mRNA

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 3

decreases expression

Ritonavir results in decreased expression of E2F3 mRNA

NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

affects expression

Ritonavir affects the expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

estrogen receptor 1

decreases expression

Ritonavir results in decreased expression of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

Fas ligand

decreases expression

Ritonavir results in decreased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

affects expression

Ritonavir affects the expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

increases expression

Ritonavir results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Ritonavir results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

galactosidase, beta 1

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; FTI 277 inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glycerol-3-phosphate dehydrogenase 1

multiple interactions

Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

heme oxygenase 1

multiple interactions
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Bilirubin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]; NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Lopinavir results in increased expression of HMOX1 mRNA]; Rotenone inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; tricarbonyldichlororuthenium (II) dimer promotes the reaction [Ritonavir results in increased expression of HMOX1 protein]
Ritonavir results in increased expression of HMOX1 mRNA; Ritonavir results in increased expression of HMOX1 protein

PMID:15504750 PMID:26968795

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein 90 alpha family class A member 1

affects response to substance

HSP90AA1 protein affects the susceptibility to Ritonavir

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family H (Hsp110) member 1

increases expression

Ritonavir results in increased expression of HSPH1 protein

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

intercellular adhesion molecule 1

increases expression
multiple interactions

Ritonavir results in increased expression of ICAM1 protein
HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

Ritonavir inhibits the reaction [IFNG protein results in increased secretion of TNF protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 6

multiple interactions
increases expression
increases secretion

diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
rosiglitazone inhibits the reaction [Ritonavir results in increased expression of IL6 mRNA]
Ritonavir results in increased expression of IL6 mRNA; Ritonavir results in increased expression of IL6 protein

PMID:15388451 PMID:15865214 PMID:17668557 PMID:20884875

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7

decreases expression

Ritonavir results in decreased expression of IL7

NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075

G

insulin 1

multiple interactions

Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Ritonavir results in increased expression of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

leptin

multiple interactions
decreases expression

diphenyleneiodonium inhibits the reaction [Ritonavir results in decreased expression of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

LIF, interleukin 6 family cytokine

decreases expression

Ritonavir results in decreased expression of LIF

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

lamin A/C

increases expression
increases farnesylation

Ritonavir results in increased expression of LMNA protein
Ritonavir results in increased farnesylation of LMNA protein alternative form

PMID:18230615 PMID:20884875

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

lipoprotein lipase

affects expression

Ritonavir affects the expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

Ritonavir results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

Ritonavir results in increased expression of NFE2L2 protein
NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

decreases activity

Ritonavir results in decreased activity of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

decreases phosphorylation

Ritonavir results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, CARD domain containing 5

decreases expression

Ritonavir results in decreased expression of NLRC5

NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121

G

nitric oxide synthase 3

multiple interactions
decreases expression

Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

notch receptor 4

decreases expression
multiple interactions

Ritonavir results in decreased expression of NOTCH4 protein
[Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of NOTCH4 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of NOTCH4 protein]

NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465

G

nuclear receptor subfamily 1, group H, member 3

increases expression

Ritonavir increases expression of NR1H3 mRNA in macrophages

RGD

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

increases expression

Ritonavir results in increased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

Ritonavir binds to and results in increased activity of NR1I2 protein
Ritonavir results in increased activity of NR1I2 protein

PMID:14977870 PMID:15849716 PMID:27732639

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

poly (ADP-ribose) polymerase 1

increases cleavage

Ritonavir results in increased cleavage of PARP1 protein

PMID:19386116 PMID:21270666

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

paraoxonase 1

decreases activity

Ritonavir results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein]
Ritonavir results in increased expression of PPARG mRNA

PMID:11101056 PMID:17879945

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase C, alpha

multiple interactions
increases activity
increases expression

Ritonavir binds to and affects the localization of PRKCA protein
Ritonavir results in increased activity of PRKCA protein
Ritonavir results in increased expression of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

proteasome 20S subunit alpha 1

affects expression

Ritonavir affects the expression of PSMA1 mRNA

NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472

G

proteasome 20S subunit beta 3

affects expression

Ritonavir affects the expression of PSMB3 mRNA

NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521

G

proteasome 20S subunit beta 5

increases expression

Ritonavir results in increased expression of PSMB5 mRNA

NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440

G

RB transcriptional corepressor 1

decreases phosphorylation
increases expression

Ritonavir results in decreased phosphorylation of RB1 protein
Ritonavir results in increased expression of RB1 mRNA

PMID:16551874 PMID:19386116 PMID:21270666

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RB transcriptional corepressor like 1

increases expression

Ritonavir results in increased expression of RBL1 mRNA

NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330

G

RB transcriptional corepressor like 2

decreases expression

Ritonavir results in decreased expression of RBL2 mRNA

NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572

G

REL proto-oncogene, NF-kB subunit

decreases activity

Ritonavir results in decreased activity of REL protein

NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892

G

RELA proto-oncogene, NF-kB subunit

decreases activity

Ritonavir results in decreased activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

scavenger receptor class B, member 1

multiple interactions
increases expression

Estradiol inhibits the reaction [Ritonavir results in increased expression of SCARB1 protein]
Ritonavir results in increased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

sterol carrier protein 2

decreases expression

Ritonavir results in decreased expression of SCP2

NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287

G

solute carrier family 10 member 1

decreases expression

Ritonavir results in decreased expression of SLC10A1

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 51 member A

decreases expression

Ritonavir results in decreased expression of SLC51A

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases phosphorylation

Ritonavir results in decreased phosphorylation of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

multiple interactions

Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 3

decreases phosphorylation

Ritonavir results in decreased phosphorylation of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tight junction protein 1

decreases expression
multiple interactions

Ritonavir results in decreased expression of TJP1 protein
[Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of TJP1 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

decreases secretion
multiple interactions
increases expression

Ritonavir results in decreased secretion of TNF protein
rosiglitazone inhibits the reaction [Ritonavir results in increased expression of TNF mRNA]
Ritonavir inhibits the reaction [IFNG protein results in increased secretion of TNF protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Ritonavir results in increased expression of TNF mRNA; Ritonavir results in increased expression of TNF protein

PMID:10551732 PMID:15388451 PMID:15865214

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions
increases expression

FTI 277 inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]

PMID:19386116 PMID:20884875

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

UDP glucuronosyltransferase family 1 member A1

affects expression

Ritonavir affects the expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

zinc metallopeptidase STE24

decreases activity

Ritonavir results in decreased activity of ZMPSTE24 protein

NCBI chr 5:134,627,218...134,660,360
Ensembl chr 5:134,627,229...134,660,110

Se-methyl-L-selenocysteine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions

[selenomethylselenocysteine co-treated with irinotecan] results in decreased expression of ABCC1

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 4

multiple interactions
decreases expression

Isoflavones promotes the reaction [selenomethylselenocysteine results in decreased expression of ABCC4 mRNA]

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

apoptotic peptidase activating factor 1

increases expression

selenomethylselenocysteine metabolite results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

androgen receptor

decreases expression

selenomethylselenocysteine results in decreased expression of AR protein
selenomethylselenocysteine results in decreased expression of AR mRNA

PMID:16637076 PMID:19025659

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2-antagonist/killer 1

increases expression

selenomethylselenocysteine metabolite results in increased expression of BAK1 mRNA

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

Btg3 associated nuclear protein

increases expression

selenomethylselenocysteine results in increased expression of BANP mRNA

NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

selenomethylselenocysteine results in decreased expression of BCL2 mRNA
selenomethylselenocysteine results in decreased expression of BCL2 protein
[selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein

PMID:11396176 PMID:19360359

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

selenomethylselenocysteine metabolite results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

increases expression

selenomethylselenocysteine metabolite results in increased expression of BCL2L11 mRNA

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

basic helix-loop-helix ARNT like 1

decreases expression

selenomethylselenocysteine results in decreased expression of BMAL1 mRNA

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

Bcl2 modifying factor

multiple interactions
increases expression

4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP9 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of PARP1 protein modified form]; HDAC8 inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; selenomethylselenocysteine metabolite inhibits the reaction [HDAC8 protein binds to BMF promoter]; selenomethylselenocysteine metabolite inhibits the reaction [STAT3 protein binds to BMF promoter]; selenomethylselenocysteine metabolite promotes the reaction [EP300 protein binds to BMF promoter]; selenomethylselenocysteine metabolite promotes the reaction [SP3 protein binds to BMF promoter]; STAT3 protein inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]
selenomethylselenocysteine metabolite results in increased expression of BMF protein
selenomethylselenocysteine metabolite results in increased expression of BMF mRNA; selenomethylselenocysteine metabolite results in increased expression of BMF protein

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

caspase 3

increases activity
increases expression
multiple interactions

selenomethylselenocysteine results in increased activity of CASP3 protein
selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form
BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form]

PMID:15318939 PMID:25321483

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

increases expression
multiple interactions

selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form
BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form]

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 8

increases expression

selenomethylselenocysteine metabolite results in increased expression of CASP8 protein modified form

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases expression

BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP9 protein modified form]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin A2

decreases expression

selenomethylselenocysteine results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

decreases expression
multiple interactions

selenomethylselenocysteine results in decreased expression of CCND1 protein
selenomethylselenocysteine results in decreased expression of CCND1 mRNA; selenomethylselenocysteine results in decreased expression of CCND1 protein
[selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of CCND1 protein

PMID:11396176 PMID:18855134 PMID:19276161

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin dependent kinase 2

multiple interactions

selenomethylselenocysteine results in decreased phosphorylation of and results in decreased activity of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

selenomethylselenocysteine metabolite results in increased expression of CDKN1A protein
[Aminooxyacetic Acid results in decreased metabolism of selenomethylselenocysteine] which results in decreased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

selenomethylselenocysteine results in increased expression of CDKN1B protein

PMID:11396176 PMID:19276161

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

carboxylesterase 1D

increases expression

selenomethylselenocysteine results in increased expression of CES1

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

charged multivesicular body protein 1A

increases expression

selenomethylselenocysteine results in increased expression of CHMP1A mRNA

NCBI chr19:51,238,153...51,246,433
Ensembl chr19:51,238,160...51,246,436

G

collagen type I alpha 1 chain

decreases expression

selenomethylselenocysteine results in decreased expression of COL1A1 mRNA; selenomethylselenocysteine results in decreased expression of COL1A1 protein

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

decreases expression

selenomethylselenocysteine results in decreased expression of COL1A2 mRNA; selenomethylselenocysteine results in decreased expression of COL1A2 protein

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type IV alpha 5 chain

increases expression

selenomethylselenocysteine results in increased expression of COL4A5 mRNA

NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692

G

collagen type VI alpha 1 chain

increases expression

selenomethylselenocysteine results in increased expression of COL6A1 mRNA

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

collagen type VII alpha 1 chain

decreases expression

selenomethylselenocysteine results in decreased expression of COL7A1 mRNA

NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252

G

cryptochrome circadian regulator 2

increases expression

selenomethylselenocysteine results in increased expression of CRY2 mRNA

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

D-box binding PAR bZIP transcription factor

increases expression

selenomethylselenocysteine results in increased expression of DBP mRNA

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

DNA-damage inducible transcript 3

increases expression

selenomethylselenocysteine results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

24-dehydrocholesterol reductase

decreases expression

selenomethylselenocysteine results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

developmentally regulated GTP binding protein 1

multiple interactions

[selenomethylselenocysteine co-treated with irinotecan] results in decreased expression of DRG1

NCBI chr14:78,103,876...78,119,976
Ensembl chr14:78,103,876...78,119,953

G

E1A binding protein p300

multiple interactions

selenomethylselenocysteine metabolite promotes the reaction [EP300 protein binds to BMF promoter]

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

estrogen receptor 1

decreases expression
multiple interactions

selenomethylselenocysteine results in decreased expression of ESR1 protein
[selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

Fas ligand

multiple interactions

[selenomethylselenocysteine co-treated with irinotecan] results in increased expression of FASLG

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

growth arrest and DNA-damage-inducible, alpha

increases expression

selenomethylselenocysteine results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glutathione peroxidase 1

increases activity
increases expression

selenomethylselenocysteine results in increased activity of GPX1 protein
selenomethylselenocysteine results in increased expression of GPX1 mRNA; selenomethylselenocysteine results in increased expression of GPX1 protein

PMID:18514395 PMID:19033020

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 4

increases expression

selenomethylselenocysteine results in increased expression of GPX4 mRNA

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutamate ionotropic receptor kainate type subunit 1

increases expression

selenomethylselenocysteine results in increased expression of GRIK1 mRNA

NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645

G

glutamate ionotropic receptor kainate type subunit 3

increases expression

selenomethylselenocysteine results in increased expression of GRIK3 mRNA

NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307

G

histone deacetylase 8

multiple interactions

HDAC8 inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; selenomethylselenocysteine metabolite inhibits the reaction [HDAC8 protein binds to BMF promoter]

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

G

insulin-like growth factor 1 receptor

increases expression

selenomethylselenocysteine results in increased expression of IGF1R mRNA

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation

selenomethylselenocysteine results in increased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kallikrein 1

decreases expression

selenomethylselenocysteine results in decreased expression of KLK3 protein

NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754

G

marker of proliferation Ki-67

multiple interactions
decreases expression

[selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of MKI67 protein
selenomethylselenocysteine results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

methionine sulfoxide reductase B1

increases expression

selenomethylselenocysteine results in increased expression of MSRB1 mRNA

NCBI chr10:13,764,883...13,770,609
Ensembl chr10:13,764,883...13,770,609

G

nuclear factor kappa B subunit 1

multiple interactions

selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prolyl 4-hydroxylase subunit alpha 1

increases expression

selenomethylselenocysteine results in increased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression

[Aminooxyacetic Acid results in decreased metabolism of selenomethylselenocysteine] which results in decreased expression of PARP1 protein modified form; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of PARP1 protein modified form]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

period circadian regulator 2

increases expression

selenomethylselenocysteine results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

increases expression

selenomethylselenocysteine results in increased expression of PER3 mRNA

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

progesterone receptor

decreases expression
multiple interactions

selenomethylselenocysteine results in decreased expression of PGR protein
[selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

protein phosphatase 1, regulatory subunit 15A

increases expression

selenomethylselenocysteine results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein kinase C, epsilon

decreases expression

selenomethylselenocysteine results in decreased expression of PRKCE protein

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

protein kinase C, zeta

decreases expression

selenomethylselenocysteine results in decreased expression of PRKCZ protein

NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367

G

RAB3B, member RAS oncogene family

increases expression

selenomethylselenocysteine results in increased expression of RAB3B mRNA

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

RAB4A, member RAS oncogene family

increases expression

selenomethylselenocysteine results in increased expression of RAB4A mRNA

NCBI chr19:51,795,613...51,822,706
Ensembl chr19:51,795,613...51,822,703

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

scavenger receptor class B, member 1

increases expression

selenomethylselenocysteine results in increased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

selenoprotein F

increases expression

selenomethylselenocysteine results in increased expression of SELENOF mRNA

NCBI chr 2:233,642,075...233,674,853
Ensembl chr 2:233,641,932...233,674,846

G

selenoprotein P

increases expression

selenomethylselenocysteine results in increased expression of SELENOP mRNA

NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852

G

selenoprotein W

increases expression

selenomethylselenocysteine results in increased expression of SELENOW mRNA

NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724
Ensembl chr 1:76,598,779...76,604,724

G

solute carrier family 3 member 1

increases uptake

SLC3A1 protein results in increased uptake of selenomethylselenocysteine

NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907

G

solute carrier family 6 member 19

increases uptake

SLC6A19 protein results in increased uptake of selenomethylselenocysteine

NCBI chr 1:29,586,191...29,604,964
Ensembl chr 1:29,586,195...29,604,962

G

solute carrier family 6 member 20a

increases uptake

SLC6A20B protein results in increased uptake of selenomethylselenocysteine

NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573

G

synaptosome associated protein 23

decreases expression

selenomethylselenocysteine results in decreased expression of SNAP23 mRNA

NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320

G

sortilin 1

increases expression

selenomethylselenocysteine results in increased expression of SORT1 mRNA

NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354

G

Sp3 transcription factor

multiple interactions

selenomethylselenocysteine metabolite promotes the reaction [SP3 protein binds to BMF promoter]

NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342

G

secreted phosphoprotein 1

decreases expression

selenomethylselenocysteine results in decreased expression of SPP1 protein

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

steroid 5 alpha-reductase 1

multiple interactions

[selenomethylselenocysteine co-treated with Isoflavones] results in decreased activity of SRD5A1 protein

NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461

G

signal transducer and activator of transcription 3

multiple interactions

selenomethylselenocysteine metabolite inhibits the reaction [STAT3 protein binds to BMF promoter]; STAT3 protein inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

syntaxin 3

increases expression

selenomethylselenocysteine results in increased expression of STX3 mRNA

NCBI chr 1:208,617,018...208,686,240
Ensembl chr 1:208,639,115...208,685,805

G

TNF superfamily member 10

multiple interactions

[selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tRNA selenocysteine 1 associated protein 1

increases expression

selenomethylselenocysteine results in increased expression of TRNAU1AP mRNA

NCBI chr 5:144,507,044...144,524,142
Ensembl chr 5:144,507,615...144,524,131

G

XPA, DNA damage recognition and repair factor

multiple interactions

selenomethylselenocysteine inhibits the reaction [Zinc binds to XPA protein]

NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726

sofosbuvir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

killer cell lectin like receptor C1

decreases expression

sofosbuvir co-treated with ledipasvir decreased expression of NCR1 protein in natural killer cells

RGD

NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425

G

natural cytotoxicity triggering receptor 1

affects expression

sofosbuvir co-treated with ledipasvir affects expression of NCR1 protein in natural killer cells

RGD

NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19808
role	19784
application	19627
NMR chemical shift reference compound	17938
ammonia	17797
organic amino compound	17797
amino acid	15928
proteinogenic amino acid	12836
pyruvate family amino acid	323
L-alanine +	106
L-leucine +	167
L-valine +	116
Path 2
Term	Annotations
CHEBI ontology	19808
subatomic particle	19806
composite particle	19806
hadron	19806
baryon	19806
nucleon	19806
atomic nucleus	19806
atom	19806
main group element atom	19756
main group molecular entity	19756
s-block molecular entity	19595
hydrogen molecular entity	19582
hydrides	19095
inorganic hydride	18093
pnictogen hydride	18082
nitrogen hydride	17989
azane	17798
ammonia	17797
organic amino compound	17797
amino acid	15928
alpha-amino acid	13848
L-alpha-amino acid	12839
pyruvate family amino acid	323
L-alanine +	106
L-leucine +	167
L-valine +	116

paths to the root